10.44 -0.05 (-0.48%) | 02-12 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 12.91 ![]() |
1-year : | 13.44 ![]() |
Resists | First : | 11.05 ![]() |
Second : | 11.51 ![]() |
Pivot price | 10.93 ![]() |
|||
Supports | First : | 10.32 ![]() |
Second : | 8.59 ![]() |
MAs | MA(5) : | 10.69 ![]() |
MA(20) : | 10.98 ![]() |
MA(100) : | 11.59 ![]() |
MA(250) : | 11.29 ![]() |
|
MACD | MACD : | -0.3 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 8.3 ![]() |
D(3) : | 15.7 ![]() |
RSI | RSI(14): 34 ![]() |
|||
52-week | High : | 13.05 | Low : | 9.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ROIV ] has closed above bottom band by 1.1%. Bollinger Bands are 7.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 10.69 - 10.76 | 10.76 - 10.82 |
Low: | 10.14 - 10.24 | 10.24 - 10.31 |
Close: | 10.3 - 10.44 | 10.44 - 10.54 |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Wed, 12 Feb 2025
Roivant Sciences: Earnings Reveal Strategic Clinical Advances - MSN
Wed, 12 Feb 2025
Roivant Sciences Ltd. (ROIV): A Cheap Biotech Stock to Invest In Now - Yahoo Finance
Wed, 12 Feb 2025
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts - Yahoo Finance
Wed, 12 Feb 2025
Industry Analysts Just Upgraded Their Roivant Sciences Ltd. (NASDAQ:ROIV) Revenue Forecasts By 21% - Simply Wall St
Tue, 11 Feb 2025
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Call Transcript - Insider Monkey
Mon, 10 Feb 2025
Roivant Sciences: Strong Earnings Call Amid Challenges - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | -473 (M) |
Shares Float | 0 (M) |
Held by Insiders | 7.2795e+008 (%) |
Held by Institutions | 3.5745e+008 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | -4.2308e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 5.53 |
Profit Margin | 3 % |
Operating Margin | 725 % |
Return on Assets (ttm) | -7 % |
Return on Equity (ttm) | 446.1 % |
Qtrly Rev. Growth | 128.9 % |
Gross Profit (p.s.) | 125 |
Sales Per Share | 102.99 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1.2e+009 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 1.88 |
Price to Sales | 0.1 |
Price to Cash Flow | 0 |
Dividend | 4.488e+007 |
Forward Dividend | 4.42e+007 |
Dividend Yield | 429885000% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |